DMAA 50MG/ML

What is DMAA (1,3-Dimethylamylamine)?

DMAA (known chemically as 1,3-dimethylamylamine, Methylhexanamine, Forthane, or 4-methylhexan-2-amine) is a simple aliphatic alkylamine compound featuring a six-carbon branched chain structure. Originally developed in the 1940s as a synthetic nasal vasoconstrictor, DMAA functions as an indirect sympathomimetic agent that mimics catecholamine activity within cellular and vascular tissue models. Unlike aromatic amphetamine derivatives, DMAA lacks a central benzene ring, operating primarily through aliphatic adrenergic receptor engagement and central monoamine transporter inhibition.

Formulated and analytical batch-tested for NobleChems, DMAA is supplied as a high-purity reference aqueous solution with a concentration of 50MG/mL for laboratory screening. Researchers investigating catecholamine release, alpha-adrenergic signaling, and comparative monoaminergic pathways frequently utilize DMAA alongside alternative neuro-chemical reference standards. For instance, evaluating Fladrafinil’s allows laboratories to contrast selective central DAT inhibition against the peripheral adrenergic vasopressor cascades characteristic of aliphatic alkylamines.

Chemical and Molecular Data

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of DMAA in laboratory research include:

• Indirect Sympathomimetic Catecholamine Release: Research demonstrates that DMAA acts as a substrate for presynaptic monoamine transporters, facilitating the localized release of endogenous norepinephrine (noradrenaline) into synaptic cleft models. This indirect sympathomimetic mechanism triggers downstream adrenergic cascade signaling in isolated tissue preparations.

• Alpha-1 and Alpha-2 Adrenergic Receptor Engagement: In vascular smooth muscle assays, DMAA exhibits affinity for alpha-1 (α1) and alpha-2 (α2) adrenergic receptors. Receptor binding stimulates intracellular calcium mobilization, resulting in marked vasoconstriction and elevated perfusion pressure in isolated organ tissue models.

• Norepinephrine & Dopamine Transporter (NET / DAT) Reuptake Inhibition: In vitro radioligand binding assays confirm that DMAA weakly inhibits the reuptake of norepinephrine and dopamine via human monoamine transporters. This dual action extends synaptic neurotransmitter residence times in neuronal cell culture assays.

What do Preclinical & Pharmacological Assays Show for DMAA?

When evaluating research efficacy and published scientific literature for DMAA (1,3-dimethylamylamine):

• Sympathomimetic & Vascular Pharmacodynamics: Classical and modern pharmacological studies cataloged in ScienceDirect evaluate the pressor responses and receptor kinetics of aliphatic alkylamines. Experimental data demonstrate that 4-methylhexan-2-amine produces dose-dependent vascular smooth muscle contraction and transient elevations in vascular resistance in animal tissue assays.

• Chemical Profiling & Mass Spectrometry Data: Official structural characterization cataloged on PubChem documents the nuclear magnetic resonance (NMR) spectrum, gas chromatography-mass spectrometry (GC-MS) fragmentation patterns, and salt solubility parameters of 1,3-dimethylamylamine for analytical reference verification.

• Comparative Monoamine Transporter Binding Assays: Competitive binding studies in cell lines expressing recombinant human NET and DAT receptors confirm that while DMAA exhibits sympathomimetic activity, its affinity for monoamine transporters is significantly lower than that of classical catecholaminergic compounds, operating primarily via indirect displaced release mechanics.

How does DMAA compare to other compounds?

To evaluate chemical structures, sympathomimetic potency, and monoamine selectivity, researchers compare DMAA against alternative central nervous system modulators and nootropic reference compounds available at NobleChems:

Frequently Asked Questions (FAQs)

1. What is the structural classification of DMAA?

DMAA (1,3-dimethylamylamine / 4-methylhexan-2-amine) is an aliphatic alkylamine. Unlike aromatic central nervous system stimulants, DMAA possesses a saturated seven-carbon branched alkyl chain with an amine group at position 2, lacking any phenyl or aromatic ring structures.

2. How does DMAA exert its sympathomimetic effects in laboratory assays?

DMAA operates primarily as an indirect sympathomimetic agent. In presynaptic nerve terminal models, it promotes the displacement and release of stored norepinephrine into the synaptic cleft, where the neurotransmitter activates postsynaptic alpha-1 and alpha-2 adrenergic receptors.

3. What are the solubility parameters of DMAA reference powder?

DMAA hydrochloride salt is readily soluble in polar solvents, including water, ethanol, and dimethyl sulfoxide (DMSO). For cell culture or tissue bath assays, reference solutions should be freshly prepared using sterile laboratory buffers or ultra-pure water to ensure exact concentration accuracy.

4. How does DMAA research differ from Fladrafinil research?

DMAA is an aliphatic sympathomimetic that causes pronounced peripheral vascular smooth muscle contraction via adrenergic release. In contrast, Fladrafinil is a centrally selective dopamine reuptake inhibitor that modulates wakefulness pathways without inducing acute peripheral vasopressor spikes.

5. What are the compliance and storage guidelines for DMAA at NobleChems?

DMAA provided by NobleChems is strictly for laboratory, in vitro, and analytical research use only (RUO). It is not for human or animal consumption. Reagent vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) protected from humidity and heat.